|
WO2020099526A1
|
|
Method for diagnosis and treating peripheral neuropathies
|
|
FR3101887A1
|
|
Genetically modified human stem cell expressing a mutant human cytochrome P450 2B6 protein and its use in the treatment of cancer
|
|
FR3101886A1
|
|
Genetically modified human stem cell expressing a mutant human cytochrome P450 2B6 protein and its use in the treatment of cancer
|
|
EP3748553A1
|
|
Method for determining an optimal drug dosing regimen
|
|
EP3748647A1
|
|
Method for detecting risk of torsades de pointes
|
|
EP3744312A1
|
|
Green tea catechins eutectic system
|
|
EP3716106A1
|
|
Method for designing and validating the shape and positioning of a cannula for a patient by simulating the insertion into the trachea
|
|
EP3714888A1
|
|
Compounds for use in the treatment of adcy5-related dyskinesia
|
|
FR3092000A1
|
|
INJECTION CANNULA, ECMO SYSTEM
|
|
EP3685858A1
|
|
A noradrenergic system stimulator in the treatment of central hypoventilation syndromes
|
|
US2019134006A1
|
|
Method of treating multiple sclerosis
|
|
CA3086762A1
|
|
System for measuring the mean arterial pressure
|
|
EP3660144A1
|
|
Osteoblasts derived from oral neuroectodermal stem cells and their use in jaw repair
|
|
EP3660145A1
|
|
Use of oligodendrocytes from oral neuroectodermal stem cells in the repair of the nervous system
|
|
EP3660048A1
|
|
Treatment of acute gvhd using donor-specific anti-hla antibodies
|
|
EP3486333A1
|
|
Method for determining individual susceptibility to developing persistent macrophagic myofasciitis
|
|
EP3646860A1
|
|
Baclofen for use in the topical treatment of localized musculoskeletal pain
|
|
EP3646884A1
|
|
Method for estimating survival of colchicine-intoxicated patients
|
|
FR3085836A1
|
|
Implant of lateralization and tensioning of the deltoid muscle
|
|
EP3679155A1
|
|
Method to confirm variants in ngs panel testing by snp genotyping
|
